135159-51-2

基本信息
盐酸沙格雷酯
(+/-)-2-(二甲胺基)-1-{[2-(3-甲氧基苯基)苯氧基]甲基}乙基丁二酸单酯盐酸盐
SARPOGRELATE HCL
SARPOGRELATE HYDROCHLORIDE
Anplag
Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester, hydrochloride (9CI)
Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester, hydrochloride, (+-)-
MCI 9042
(+/-)-2-(Dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride
(+/-)-2-(Dimethylamino)-1-{[o-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride
物理化学性质
制备方法

108-30-5

135963-42-7

135159-51-2
1. 将1-二甲氨基-3-[2-[2-(3-甲氧基苯基)乙基]苯氧基]-2-丙醇(29.8g,0.090mol)和琥珀酸酐(11.3g,0.113mol)溶解于丙酮(200ml)中。2. 加热混合物至回流状态,维持反应6小时。3. 反应完成后,将混合物置于冰浴中冷却至0~5℃。4. 向冷却的混合物中缓慢通入干燥的氯化氢气体,调节pH值至1~2,此时有白色固体析出。5. 缓慢升温至室温,继续搅拌8小时以确保反应完全。6. 过滤收集白色固体,干燥后使用丙酮进行重结晶。7. 最终得到白色固体盐酸沙格雷酯(38.8g,收率92.5%),经检测纯度为99.8%。
参考文献:
[1] Patent: CN103965063, 2016, B. Location in patent: Paragraph 0019; 0023; 0027
常见问题列表
Target | Value |
5-HT2A
(Cell-free) | 0.2 nM(Kd) |
5-HT2C
(Cell-free) | 1.1 nM(Kd) |
5-HT2B
(Cell-free) | 2.1 nM(Ki) |
5-HT2B
(Cell-free) | 2.1 nM(Kd) |
Sarpogrelate is selective for 5-HT
2
(pK
i
=7.54) over 5-HT
1
(pK
i
=4.58), α
1
-, α
2
-, and β-adrenergic (pK
i
=3.17-6.19), and muscarinic receptors (pK
i
=4.39).
Sarpogrelate (10 μM) significantly reduces the number of platelet-rich plasma (PRP)-induced THP-1 cell that adheres to human umbilical vein endothelial cells (HUVECs).
Sarpogrelate (10 μM) significantly reduces the expression of PRP-induced E-selectin in HUVECs.
Sarpogrelate (5 mg/kg; i.p. daily for 4 weeks) inhibits HFFD-induced obesity and decreases leukocyte-endothelial interactions in mice.
Animal Model: | Male C57BL/6 mice (7 weeks old) are fed normal chow (NC) or a high-fat diet with 30% fructose in the drinking water (HFFD) |
Dosage: | 5 mg/kg |
Administration: | I.p. daily for 4 weeks |
Result: |
Prevented the HFFD-induced increases of the body weight, visceral fat weight, and serum monocyte chemoattractant protein-1 levels.
Decreased leukocyte-endothelial interactions and serum monocyte chemoattractant protein-1 (MCP-1) level. |